LIVE Day Two: 2019 MassBio Annual Meeting, State of Possible Conference, Sonesta Hotel, Cambridge, March 28, 2019
http://files.massbio.org/file/MassBio-State-Of-Possible-Conference-Agenda-Feb-22-2019.pdf
Leaders in Pharmaceutical Business Intelligence (LPBI) Group
represented by Founder & Director, Aviva Lev-Ari, PhD, RN will cover this event in REAL TIME using Social Media
Day 2 Agenda – March 28, 2019
|
Day 2 Agenda – March 28, 2019 |
|
8:15am – 8:45am: Breakfast 8:45am – 9:00am: Possible Talk Possible Talk – The New Role of Police: Creating Non-Arrest Pathways to Treatment and Recovery
9:00am – 9:45am: Future of Human Biology: How we are Already Evolving Ourselves Megan Thielking, STAT News
9:45am – 10:00am: Possible Talk – Possible Talk – The Evolution of the Investment Landscape to Support Future Innovations in Biotech
10:15am – 11:00am: CFIUS: Proposed Rules Impacting Global Investment for Biotech [Business Track]
10:15am – 11:00am: Exploring the Possibilities of Microbiome Beyond GI Diseases [Science Track]
11:00am – 11:30am: Networking Break 11:30am – 12:15pm: Advancing from ‘R’ to ‘D’: Various Routes to Building Successful Clinical-stage Companies [Science Track]
11:30am – 12:15pm: Financing Outlook for 2019-2020: Will the Bubble Burst? [Business Track]
12:15pm – 1:15pm: Lunch and MassBio Innovation Award Presentation
1:15pm – 2:00pm: Enabling Digital Health in the Healthcare Value Chain Moderator: Hussain Mooraj, Delloitte
2:00pm – 2:30pm: Keynote Address
2:30pm – 3:00pm: Closing Networking Dessert Reception |
@@@@@
8:15am – 8:45am: Breakfast
8:45am – 9:00am: Possible Talk
9:00am – 9:45am: Future of Human Biology: How we are Already Evolving Ourselves Humans began changing our environment early on through fire, agriculture and early medicines, and later with biopharmaceuticals and even CRISPR babies. Come hear futurists in human biology offer provocative thoughts on how we can wisely and ethically embrace next generation science to change our own DNA. – George M. Church Phd, Professor of Genetics, Harvard Medical School – Juan Enriquez, Managing Director, Excel Venture Management – Greg Verdine, President, CEO & CSO, Board Member, LifeMine
9:45am – 10:00am: Possible Talk
10:15am – 11:00am: CFIUS: Will New Regulatory Threats Reduce Global Investment in Biotech? [Business Track] CFIUS’ newly expanded scope and authority have the potential to severely disrupt investment in the U.S. biotech sector. A new federal law now includes biotechnology on a list of 27 “critical” industries where all foreign investment must be reviewed by the CFIUS office. With this new rule in place, questions abound about its impact on the biotech industry. Will raising money take longer? Will it deter foreign investors? Will it limit companies’ leverage during investment negotiations? Come hear legal, investor, and company experts discuss what companies and investors need to know about CFIUS’ impact on future investments in biotech companies. – Vikas Goyal, Principal, S. R. One, Limited – Linda Ji, Partner, McDermott Will & Emory – Lisa Schaefer, Director of Financial Services and Tax Policy, Biotechnology Innovation Organization (BIO)
10:15am – 11:00am: Exploring the Possibilities of Microbiome Beyond GI Diseases [Science Track] The specific balance of bacteria in your gut affects your digestive system, but new research also shows these bacteria affect your behavior, energy, heart, brain and other unexpected organ systems. Pioneers in microbiome expound on the possibilities. – David Donabedian, Co-founder, CEO & Director, Axial Biotherapeutics – Justin Chakma, Head of BD and Strategy, Vedanta – Chris Howerton, Biotechnology Equity Analyst, Jeffries
11:00am – 11:30am: Networking Break
11:30am – 12:15pm: Advancing from ‘R’ to ‘D’: Various Routes to Building Successful Clinical-stage Companies [Science Track] Massachusetts is the epicenter of startup creation for biotech, but it’s not always easy to go from research to commercialization. Come hear founders and industry leaders offer lessons learned on intelligently scaling your company amid rapid growth including when to partner, sell or IPO, or when to build or buy preclinical, manufacturing, and clinical development capabilities. – Laura Indolfi, Founder & CEO, PanTher Therapeutics – Sven Karlsson, Co-Founder, CEO,& CBO, Platelet Biogenesis – Leslie Williams, Director, Founder, President and CEO, ImmusanT
11:30am – 12:15pm: Financing Outlook for 2019-2020: Will the Bubble Burst? [Business Track] 2018 was a record year for biotech IPOs, the XBI hit an all-time high in August, and the FDA approved a record number of novel drugs. What will 2019 bring after late 2018’s many signals of a slowing market? Will M&A pick up? Can new IPOs continue at last year’s pace? How will public markets respond? Investment bankers, private equity, and industry leaders peer into their crystal ball to predict the financial outlook for the next few years. – Bruce Booth, Partner, Atlas Ventures
12:15pm – 1:15pm: Lunch and MassBio Innovation Award Presentation
1:15pm – 2:00pm: Enabling Digital Health in the Healthcare Value Chain At its core, digital technologies are increasingly critical in enabling the growth of biotechnology companies– from the development of better research and development insight engines, to the commercialization of next generation therapies via digital channels. This panel will explore best practices that enable the embedding of digital health technologies in the value chain for both life sciences companies, payers and providers.
2:00pm – 2:30pm: Keynote Address
2:30pm – 3:00pm: Closing Networking Dessert Reception
2012pharmaceutical
sjwilliamspa
Leave a Reply